Robert Hombach - Biomarin Pharmaceutical Independent Director
| BMRN Stock | USD 89.49 0.86 0.97% |
Director
Mr. Robert J. Hombach, CPA, is Independent Director of the Company. Hombach joined our Board in September 2017. He served as Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta Inc., a public biopharmaceutical company spun out in June 2015 from Baxter International Inc., a public pharmaceutical company, until it was acquired by Shire PLC in June 2016. He served as Corporationrationrate Vice President and Chief Financial Officer of Baxter from July 2010 until the spinoff. From 2007 to 2011, he also served as Treasurer of Baxter and from 2004 to 2007, he was Vice President of Finance, Europe, Middle East and Africa. Prior to that, he served in a number of finance positions of increasing responsibility in the corporate planning, manufacturing, operations and treasury areas at Baxter. Mr. Hombach currently serves on the board of CarMax, Inc., a public company. Previously, he served on the board of Naurex, Inc., a private pharmaceutical company acquired by Allergan in 2015 since 2017.
| Age | 51 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 770 Lindaro Street, San Rafael, CA, United States, 94901 |
| Phone | 415 506 6700 |
| Web | https://www.biomarin.com |
Biomarin Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0163 % which means that it generated a profit of $0.0163 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0351 %, meaning that it created $0.0351 on every $100 dollars invested by stockholders. Biomarin Pharmaceutical's management efficiency ratios could be used to measure how well Biomarin Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of April 2024, Return On Tangible Assets is likely to grow to 0.03. Also, Return On Capital Employed is likely to grow to 0.03. At this time, Biomarin Pharmaceutical's Return On Tangible Assets are very stable compared to the past year. As of the 23rd of April 2024, Fixed Asset Turnover is likely to grow to 2.28, while Non Currrent Assets Other are likely to drop about 72.7 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| George Poste | Exelixis | 73 | |
| Edward Mathers | Liquidia Technologies | 57 | |
| Peter Bains | Mereo BioPharma Group | 61 | |
| Lynne Parshall | Ionis Pharmaceuticals | 63 | |
| Wendy Dixon | Incyte | 62 | |
| JeanJacques Bienaime | Incyte | 64 | |
| Kunal Kashyap | Mereo BioPharma Group | 52 | |
| Richard Jones | Mereo BioPharma Group | 50 | |
| Colleen Reitan | Alnylam Pharmaceuticals | 58 | |
| Spencer Berthelsen | Ionis Pharmaceuticals | 65 | |
| JeanPierre Bizzari | Halozyme Therapeutics | 63 | |
| Michael Landsittel | Blueprint Medicines Corp | 52 | |
| Joseph Wender | Ionis Pharmaceuticals | 73 | |
| Julie Smith | Exelixis | 47 | |
| Deepa Pakianathan | Mereo BioPharma Group | 53 | |
| Marsha Fanucci | Alnylam Pharmaceuticals | 64 | |
| Ingrid Leisner | Bio Techne Corp | N/A | |
| Alan Garber | Exelixis | 62 | |
| Stephen Knight | Blueprint Medicines Corp | 55 | |
| William Waddill | Arrowhead Pharmaceuticals | 60 | |
| Kendra Adams | Agios Pharm | N/A | |
Management Performance
| Return On Equity | 0.0351 | ||||
| Return On Asset | 0.0163 |
Biomarin Pharmaceutical Leadership Team
Elected by the shareholders, the Biomarin Pharmaceutical's board of directors comprises two types of representatives: Biomarin Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biomarin. The board's role is to monitor Biomarin Pharmaceutical's management team and ensure that shareholders' interests are well served. Biomarin Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biomarin Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elaine Heron, Independent Director | ||
| Dennis Slamon, Director | ||
| Henry Fuchs, Executive Vice President and Chief Medical Officer | ||
| George Davis, Chief VP | ||
| Robert Hombach, Independent Director | ||
| Philip Scalzo, VP Officer | ||
| JeanJacques Bienaime, Chairman of the Board, CEO | ||
| Jeff Ajer, Executive Vice President Chief Commercial Officer | ||
| Richard Meier, Independent Director | ||
| Willard Dere, Director | ||
| Amy Wireman, Executive Officer | ||
| Jeffrey Ajer, Executive Officer | ||
| Eric Davis, Sr. VP, General Counsel and Secretary | ||
| Pierre Lapalme, Independent Chairman of the Board | ||
| Robert Baffi, Executive VP of Technical Operations | ||
| Richard Ranieri, Senior Vice President - Human Resources and Corporate Affairs | ||
| Elizabeth Anderson, Independent Director | ||
| Traci McCarty, Group Relations | ||
| Jonathan Day, Executive Science | ||
| Marni Kottle, Executive Officer | ||
| Humaira Serajuddin, Senior Officer | ||
| Brian Mueller, Chief Accounting Officer, Group VP and Controller | ||
| Liz Anderson, Director | ||
| Erin Burkhart, Group Officer | ||
| Bryan Lawlis, Independent Director | ||
| Greg Guyer, Executive Officer | ||
| Ganesh Vedantham, Senior Development | ||
| Daniel Spiegelman, CFO, Executive Vice President | ||
| Kevin Eggan, Chief Development | ||
| Yen Wing, Vice Science | ||
| Kathryn Falberg, Director | ||
| Alexander Hardy, CEO President | ||
| MBA MBA, Chairman CEO | ||
| Alan Lewis, Independent Director | ||
| David Pyott, Independent Director | ||
| Michael Grey, Independent Director |
Biomarin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biomarin Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0351 | ||||
| Return On Asset | 0.0163 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.04 % | ||||
| Current Valuation | 16.78 B | ||||
| Shares Outstanding | 189.78 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 99.16 % | ||||
| Number Of Shares Shorted | 3.06 M | ||||
| Price To Earning | 220.73 X |
Biomarin Pharmaceutical Investors Sentiment
The influence of Biomarin Pharmaceutical's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Biomarin. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Biomarin Pharmaceutical's public news can be used to forecast risks associated with an investment in Biomarin. The trend in average sentiment can be used to explain how an investor holding Biomarin can time the market purely based on public headlines and social activities around Biomarin Pharmaceutical. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Biomarin Pharmaceutical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Biomarin Pharmaceutical's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Biomarin Pharmaceutical's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Biomarin Pharmaceutical.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Biomarin Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Biomarin Pharmaceutical's short interest history, or implied volatility extrapolated from Biomarin Pharmaceutical options trading.
Pair Trading with Biomarin Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Biomarin Stock
| 0.74 | PBH | Prestige Brand Holdings Financial Report 2nd of May 2024 | PairCorr |
| 0.62 | RDY | Dr Reddys Laboratories Financial Report 8th of May 2024 | PairCorr |
| 0.62 | SUPN | Supernus Pharmaceuticals Financial Report 14th of May 2024 | PairCorr |
| 0.61 | KROS | Keros TherapeuticsInc Financial Report 2nd of May 2024 | PairCorr |
| 0.61 | MRUS | Merus BV Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Biomarin Stock analysis
When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.98 | Earnings Share 0.87 | Revenue Per Share 12.88 | Quarterly Revenue Growth 0.202 | Return On Assets 0.0163 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.